Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metronomic Chemotherapy
Marina Elena Cazzaniga, Nicoletta Cordani, Serena Capici, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2236-2236
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Advances in medical treatment of breast cancer in 2022
Jingtong Zhai, Yun Wu, Fei Ma, et al.
Cancer Innovation (2023) Vol. 2, Iss. 1, pp. 1-17
Open Access | Times Cited: 28
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
Nusrat Jan, Shazia Sofi, Hina Qayoom, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e24670-e24670
Open Access | Times Cited: 15
Transplant oncology and anti-cancer immunosuppressants
Dejun Kong, Jinliang Duan, Shiyi Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence
Apoorv Kirti, Faizan Zarreen Simnani, Snehasmita Jena, et al.
Cancer Letters (2024) Vol. 594, pp. 216990-216990
Closed Access | Times Cited: 7
Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach
Farshad Moradi Kashkooli, M. Soltani
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 38
Optimizing the future: how mathematical models inform treatment schedules for cancer
Deepti Mathur, Ethan S. Barnett, Howard I. Scher, et al.
Trends in cancer (2022) Vol. 8, Iss. 6, pp. 506-516
Open Access | Times Cited: 25
Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
Piotr J. Wysocki, Mateusz Łobacz, Paweł Potocki, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1067-1067
Open Access | Times Cited: 15
Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
Elena Muraro, Lorenzo Vinante, Elisabetta Fratta, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2471-2471
Open Access | Times Cited: 15
Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
Vijay Kumar Panthi, Kamal Dua, Sachin Kumar Singh, et al.
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1192-1192
Open Access | Times Cited: 13
Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF-kB signaling pathway
Zheng Cai, Lang Gao, Kai Hu, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 7, pp. 895-907
Closed Access | Times Cited: 5
Emerging actionable targets to treat therapy-resistant colorectal cancers
Emanuela Grassilli, Maria Grazia Cerrito
Cancer Drug Resistance (2022)
Open Access | Times Cited: 19
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 16, pp. 4710-4710
Open Access | Times Cited: 19
Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data
Anna Buda-Nowak, Łukasz Kwinta, Paweł Potocki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1350-1350
Open Access | Times Cited: 11
Metronomic chemotherapy in cancer treatment: new wine in an old bottle
Huailiang Wu, Han-Xing Zhou, Limin Chen, et al.
Theranostics (2024) Vol. 14, Iss. 9, pp. 3548-3564
Open Access | Times Cited: 4
Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress
Vlad Iova, R.C. Tincu, Ioana Scrobotă, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 981-981
Open Access
Efficacy of immune checkpoint inhibitors rechallenge and metronomic cyclophosphamide with or without bevacizumab in metastatic nonsmall cell lung cancer
A. A. Musaelyan, Svetlana V. Odintsova, Magaripa A. Urtenova, et al.
Anti-Cancer Drugs (2025)
Closed Access
The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
Mirosława Püsküllüoğlu, Izabela Michalak
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules
Marta Banchi, Maria Christina Cox, Guido Bocci
Cancer Letters (2024) Vol. 591, pp. 216900-216900
Open Access | Times Cited: 3
Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology
Gonçalo N. Petrucci, Tomás Rodrigues Magalhães, Márcia Dias, et al.
Frontiers in Veterinary Science (2024) Vol. 11
Open Access | Times Cited: 3
Canine lung carcinoma—A descriptive review
A. Marcinowska, Rodrigo dos Santos Horta, Felisbina L. Queiroga, et al.
Frontiers in Veterinary Science (2025) Vol. 11
Open Access
Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling
Aryan Golzaryan, M. Soltani, Farshad Moradi Kashkooli, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Myeloid-Derived Suppressor Cells: Implications in Cancer Immunology and Immunotherapy
Juan F. Santibáñez
Frontiers in Bioscience-Landmark (2025) Vol. 30, Iss. 3
Open Access
Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal
Luca Roncati
Cancers (2025) Vol. 17, Iss. 8, pp. 1323-1323
Open Access
The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer: The ELCAPA Cohort Study
Florence Canouï‐Poitrine, Lauriane Ségaux, Marc‐Antoine Benderra, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2236-2236
Open Access | Times Cited: 16
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors
Simone Nardin, G. Sacco, Agostina Lagodin D’Amato, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 8, pp. 1051-1069
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top